Full Schedule

7:45 AM - 8:00 AM HST

Response Assessment in CML

Presenter: – Fred Hutch Cancer Center

7:45 AM - 9:45 AM HST

Moderator

Moderator: – Imperial College London

Moderator: – Augusta University

8:00 AM - 8:15 AM HST

Tyrosine Kinase Inhibitor (TKI) in Upfront Management of CML: Is One Superior to Others?

Presenter: – University of Nebraska Medical Center

8:15 AM - 8:30 AM HST

Management of CML Not Meeting Milestones

Presenter: – The University of Texas MD Anderson Cancer Center

8:30 AM - 8:45 AM HST

3rd Generation ABL1 Kinase Inhibitors – When and How to Use Them

Presenter: – Augusta University

9:00 AM - 9:15 AM HST

Stopping Tyrosine Kinase Inhibitor in CML: When and How

Presenter: – Augusta University

9:15 AM - 9:30 AM HST

Mitigating Toxicities Associated with TKI

Presenter: – Imperial College London

10:05 AM - 10:20 AM HST

Optimal Upfront Treatment in CLL: A Moving Target (Younger Patients)

Presenter: – University of Nebraska Medical Center

10:05 AM - 11:45 AM HST

Moderator

Moderator: – University of Nebraska Medical Center

10:20 AM - 10:35 AM HST

Optimal Upfront Treatment in CLL: A Moving Target (Older Patients)

Presenter: – The University of Texas MD Anderson Cancer Center

10:50 AM - 11:05 AM HST

Double Refractory CLL: An Emerging Clinical Challenge

Presenter: – University of California Irvine

11:05 AM - 11:20 AM HST

Richter Transformation

Presenter: – The University of Texas MD Anderson Cancer Center

11:35 AM - 11:45 AM HST

Concluding Remarks

Moderator: – The University of Texas MD Anderson Cancer Center